Latest News for KLRA
WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the pricing of its initial public offering of 39,062,500 shares of its common stock at a price to the public of $16.00 per share.
Kailera Therapeutics is targeting an IPO to fund GLP-1-based obesity treatments, led by ribupatide, with positive efficacy data versus tirzepatide. KLRA is well-capitalized with $546 million in cash, strong investor backing, and an experienced management team, positioning it for extensive clinical development. Ribupatide demonstrated a 23.6% mean weight reduction over 12 weeks at 8 mg in late-stage trials, outpacing…
Kailera Therapeutics has filed for a U.S. initial public offering, it said in a filing on Friday.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for KLRA.
Senate Trading
No Senate trades found for KLRA.
U.S. House Trading
No House trades found for KLRA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.